Albert Einstein Healthcare Network
Trial Pipeline
Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain.Home-Based Treatment
NCT07044323
Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton
NCT06225830
GetUp&Go: A Randomized Controlled Trial of an Intervention to Enhance Physical Activity After TBI
NCT06028334
Motor Learning After Cerebellar Damage: The Role of the Primary Motor Cortex
NCT05351255
Evaluate the Clinical Benefits of EnvarsusXR in Post Liver Transplant
NCT03386305
Perceptual-motor Interaction to Improve Bimanual Coordination After Stroke
NCT03755076
Adjunctive Nitrous Oxide During Emergency Department Propofol Sedation in Adults
NCT02410707
SMS Messaging to Reduce Depression and Anxiety Following TBI
NCT02061553
Use of a Single Dose of Oral Prednisone in the Treatment of Cellulitis
NCT01671423
The Use of Incentives to Promote Healthier Eating in Low-income Communities
NCT01616628
Study of Left Ventricular Dyssynchrony in Heart Failure Patients
NCT00953953
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 1 |
Therapeutic Areas
What the Pipeline for Albert Einstein Healthcare Network Shows
According to the ClinicalTrials.gov registry, Albert Einstein Healthcare Network is linked to 39 US clinical trials across every stage of research activity. Of those, 30 studies are currently recruiting — about 77% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 15% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Albert Einstein Healthcare Network reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 2 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Albert Einstein Healthcare Network is Traumatic Brain Injury with 2 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.